Global HIV Treatment Market: Analysis By Product (Atripla, Biktarvy, Descovy, Genovya, Odefsey, Truvada, Sunlenca (Lenacapavir), Dovato, Juluca, Tivicay, Triumeq, Cabenuva, VH184, Capsid, bNAbs, Islatravir, and Generics), By Region (The US, and EU + ROW)

Global HIV Treatment Market: Analysis By Product (Atripla, Biktarvy, Descovy, Genovya, Odefsey, Truvada, Sunlenca (Lenacapavir), Dovato, Juluca, Tivicay, Triumeq, Cabenuva, VH184, Capsid, bNAbs, Islatravir, and Generics), By Region (The US, and EU + ROW) Size and Trends with Impact of COVID-19 and Forecast up to 2030


The global HIV treatment market in 2022 stood at US$22.38 billion, and is likely to reach US$25.49 billion by 2030. HIV treatment, also known as antiretroviral therapy (ART), involves the use of medications to manage the human immunodeficiency virus (HIV). Antiretroviral therapy (ART) for HIV treatment is a combination of drugs that work to slow the rate at which the virus replicates within the body, preventing it from progressing to AIDS. This helps maintain the immune system's health, reduces the risk of transmission, and enhances the patient's quality of life.

In recent years, the surge in demand for HIV treatment is driven by a rise in global HIV prevalence, enhanced diagnostic capabilities, progress in treatment methodologies, and the advent of innovative drugs with higher efficacy and resistance profiles. This is further bolstered by heightened public awareness and healthcare initiatives. To counter this, UNAIDS has set in motion the Fast-Track strategy with the objective of eradicating the AIDS epidemic as a public health threat by 2030. This strategy focuses on optimized resource allocation and expedited responses, underlining its significance in achieving the Sustainable Development Goals, specifically, ensuring health and well-being for all. Despite the absence of a definitive cure for HIV at present, ongoing research and development activities offer hope for more efficient treatments in the future. The global HIV treatment market is projected to grow at a CAGR of 1.42% during the forecast period of 2023-2030.

Market Segmentation Analysis:

By Product: The market report has segmented the global HIV treatment market into seventeen segments namely, Biktarvy, Cabenuva, Sunlenca (lenacapavir), Islatravir, Genvoya, Odefsey, bNAbs, Descovy, Capsid, Dovato, Tivicay, Juluca, VH184, Triumeq, Atripla, Truvada, and Generics. In 2022, the Biktarvy segment dominates the market share in 2022, the Biktarvy, a single-tablet regimen for HIV, holds the largest market share due to its high efficacy, minimal side effects, and convenience, coupled with its proven effectiveness across diverse patient populations, making it a preferred choice for both clinicians and patients. The HIV treatment market is poised for significant advancements due to relentless research and development activities. By the end of the 2030s, this market is expected to be augmented by the launch of novel and advanced HIV treatment drugs, thereby strengthening our global response to this major health concern. The forthcoming period is expected to witness the debut of several groundbreaking products like Sunlenca (lenacapavir), VH184, Capsid, bNAbs, and Islatravir. Concurrently, the patents of numerous existing drugs such as Descovy, Tivicay, Triumeq, Juluca, and Dovato are anticipated to expire, thereby facilitating the introduction of generic substitutes in the market.

By Region: According to this report, the global HIV treatment market can be divided into two major regions: The US, and European Union + Rest of the World (EU + ROW).

In 2022, the US dominated the global HIV treatment market due to its broad coverage of health insurance, effective HIV awareness programs, and the presence of major pharmaceutical companies engaged in HIV research and drug development.

The US HIV treatment market is expected to grow at the fastest CAGR from 2023 to 2030 due to ongoing advancements in medical technology and pharmaceuticals, spurred by continuous research from US-based companies, are leading to the development of more effective antiretroviral drugs, fueling market expansion. Moreover, enhanced HIV screening and testing initiatives are set to increase the number of diagnosed cases, thus driving demand for treatment drugs.

Global HIV Treatment Market Dynamics:

Growth Drivers: The HIV treatment market has experienced significant growth due to the development of more effective and tolerable antiretroviral treatments (ARTs), increased availability and affordability of ARTs, and growing awareness and prevention efforts. Ongoing development of innovative medications is expected to sustain market growth, benefiting individuals worldwide by improving treatment accessibility, affordability, and quality of life, while also preventing drug resistance and promoting long-term health outcomes. This growth signifies progress in the fight against HIV and the provision of necessary treatment for improved patient outcomes. Further, the market is expected to grow owing to rising HIV prevalence, rising disposable income, increased government funding and initiatives, expansion of generic drugs, growing awareness and testing, public-private partnerships, etc. in recent years.

Challenges: Drug-resistant strains of HIV pose a major challenge to the global HIV treatment market, necessitating continuous research, development of new antiretroviral therapies, and monitoring of resistance trends. Adherence to treatment regimens and ensuring the quality and availability of medications are crucial to mitigate drug resistance. Addressing these challenges is vital for maintaining the effectiveness of current treatments and developing novel therapies capable of combating drug-resistant HIV strains. Additionally, other factors like stigma, discrimination, and access to treatment, loss of patent protection, etc. are other challenges to the market.

Market Trends: Advances in gene therapy have the potential to revolutionize the global HIV treatment market, offering more targeted and effective treatment options, potential functional cures, and improved patient outcomes. Promising candidates in development indicate significant growth opportunities and market potential, transforming the treatment landscape and enhancing the quality of life for individuals living with HIV. More trends in the market are believed to grow the HIV treatment market during the forecasted period, which may include increasing penetration of artificial intelligence, increasing adoption of telemedicine, development of long-acting injectable, focus on combination therapies, etc.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic has had a mixed impact on the global HIV treatment market, resulting in disruptions to medication supply chains and patient care, but also driving increased public health awareness, telemedicine adoption, and accelerated pharmaceutical innovation amid collaborative efforts for equitable treatment distribution. The post-COVID impact on the HIV treatment market is expected to bring improved access to care, increased innovation, greater collaboration, enhanced supply chain resilience, and a focus on achieving health equity.

Competitive Landscape and Recent Developments:

The global HIV treatment market is consolidated, with major pharmaceutical companies like Gilead Sciences, ViiV Healthcare, and Merck leading the market with their comprehensive drug portfolios. These firms, with expansive drug portfolios, significantly shape the market. Notably, Gilead's Biktarvy and ViiV's Dovato offer effective treatment options with limited side effects. These companies continue to innovate, investing in research and development to improve patient outcomes and address persistent HIV challenges. Gilead's recent FDA application for lenacapavir, a long-acting HIV-1 capsid inhibitor, exemplifies their commitment to innovation. These ongoing efforts are instrumental in shaping the future of the global HIV treatment market.

Further, key players in the global HIV treatment market are:

Gilead Sciences, Inc.
GlaxoSmithKline Plc (ViiV Healthcare)
Merck & Co., Inc.
Abbott Laboratories
AbbVie Inc.
TEVA Pharmaceutical Industries Limited
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Cipla Limited
Viatris Inc.
Bristol-Myers Squibb Company
Hetero Drugs Limited

Smaller players and generic manufacturers contribute to accessibility and affordability, improving treatment outcomes globally. Collaborations and partnerships, such as the Medicines Patent Pool (MPP) and ViiV Healthcare, facilitate the production of affordable generic versions of HIV medications. Key generic players include Mylan, Cipla, Aurobindo Pharma, Hetero Drugs, and Sun Pharmaceutical Industries. Partnerships between pharmaceutical companies, NGOs, governments, and global health organizations drive research, development, and access to HIV treatments, ensuring broader availability and better patient care.

Global HIV Treatment Market: Analysis By Product (Atripla, Biktarvy, Descovy, Genovya, Odefsey, Truvada, Sunlenca (lenacapavir), Dovato, Juluca, Tivicay, Triumeq, Cabenuva, VH184, Capsid, bNAbs, Islatravir, and Generics), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030 - Report Summary
Report Metrics Details
Years Considered 2018-2028
Base Year 2022
Forecast Period 2023-2028
Page Count 169
Units Referenced US $
Segments/Key Topics By Product, By Region
Regions Covered The US and European Union + ROW
Key Companies Mentioned Gilead Sciences, Inc., GlaxoSmithKline Plc (ViiV Healthcare), Merck & Co., Inc., Abbott Laboratories, AbbVie Inc., TEVA Pharmaceutical Industries Limited, Johnson & Johnson (Janssen Pharmaceuticals), Boehringer Ingelheim, Cipla Limited, Viatris Inc., Bristol-Myers Squibb Company, and Hetero Drugs Limited

Five FAQs about the Report

What is the size of this market?
The global HIV treatment market in 2022 was valued at US$22.38 billion.

What is the forecasted growth for this market?
The US insulation market is projected to reach US$25.49 billion by 2030. The market is determined to grow at a CAGR of 1.42% over the forecasted period of 2023-2030.

What are key factors driving this market?
In recent years, the surge in demand for HIV treatment is driven by a rise in global HIV prevalence, enhanced diagnostic capabilities, progress in treatment methodologies, and the advent of innovative drugs with higher efficacy and resistance profiles. This is further bolstered by heightened public awareness and healthcare initiatives. To counter this, UNAIDS has set in motion the Fast-Track strategy with the objective of eradicating the AIDS epidemic as a public health threat by 2030.

How is this market segmented in this report?
The global HIV treatment market can be segmented on the basis of product (Atripla, Biktarvy, Descovy, Genovya, Odefsey, Truvada, Sunlenca (lenacapavir), Dovato, Juluca, Tivicay, Triumeq, Cabenuva, VH184, Capsid, bNAbs, Islatravir, and Generics).

What is the definition of this market in this report?
HIV treatment, also known as antiretroviral therapy (ART), involves the use of medications to manage the human immunodeficiency virus (HIV). Antiretroviral therapy (ART) for HIV treatment is a combination of drugs that work to slow the rate at which the virus replicates within the body, preventing it from progressing to AIDS. This helps maintain the immune system's health, reduces the risk of transmission, and enhances the patient's quality of life.
9What are the major influences driving the growth/decline of this market?
The HIV treatment market has grown significantly with effective and affordable antiretroviral treatments, and ongoing development of innovative medications is expected to further improve global accessibility and outcomes, indicating progress in the fight against HIV. Further, the market is expected to grow owing to rising HIV prevalence, increased government funding and initiatives, expansion of generic drugs, growing awareness and testing, public-private partnerships, etc. in recent years, yet the market faces some challenges such as drug resistance, stigma, discrimination, and access to treatment, etc.


1. Executive Summary
2. Introduction
2.1 HIV Treatment: An Overview
2.1.1 Definition of HIV Treatment
2.1.2 Goals of HIV Treatment
Table 1: Goals of HIV Treatment
2.1.3 HIV Treatment by Medication Class
Table 2: HIV Treatment by Medication Class
2.2 HIV Treatment Segmentation: An Overview
2.2.1 HIV Treatment Segmentation by Product
Table 3: HIV Treatment Segmentation by Product
3. Global Market Analysis
3.1 Global HIV Treatment Market: An Analysis
3.1.1 Global HIV Treatment Market: An Overview
3.1.2 Global HIV Treatment Market by Value
Table 4: Global HIV Treatment Market by Value; 2020-2022 (US$ Billion)
Table 5: Global HIV Treatment Market by Value; 2023-2030 (US$ Billion)
3.1.3 Global HIV Treatment Market by Product (Biktarvy, Genvoya, Triumeq, Dovato, Tivicay, Odefsey, Juluca, Descovy, Cabenuva, Truvada, Atripla, and Generics)
Table 6: Global HIV Treatment Market by Product; 2022 (Percentage, %)
3.1.4 Global HIV Treatment Market by Region (the US, and European Union + Rest of World)
Table 7: Global HIV Treatment Market by Region; 2022 (Percentage, %)
3.2 Global HIV Treatment Market: Product Analysis
3.2.1 Global HIV Treatment Market by Product: An Overview
3.2.2 Global Biktarvy HIV Treatment Market by Value
Table 8: Global Biktarvy HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 9: Global Biktarvy HIV Treatment Market by Value, 2023-2030 (US$ Billion)
3.2.3 Global Genvoya HIV Treatment Market by Value
Table 10: Global Genvoya HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 11: Global Genvoya HIV Treatment Market by Value, 2023-2030 (US$ Billion)
3.2.4 Global Triumeq HIV Treatment Market by Value
Table 12: Global Triumeq HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 13: Global Triumeq HIV Treatment Market by Value, 2023-2030 (US$ Million)
3.2.5 Global Dovato HIV Treatment Market by Value
Table 14: Global Dovato HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 15: Global Dovato HIV Treatment Market by Value, 2023-2030 (US$ Billion)
3.2.6 Global Tivicay HIV Treatment Market by Value
Table 16: Global Tivicay HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 17: Global Tivicay HIV Treatment Market by Value, 2023-2030 (US$ Million)
3.2.7 Global Odefsey HIV Treatment Market by Value
Table 18: Global Odefsey HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 19: Global Odefsey HIV Treatment Market by Value, 2023-2030 (US$ Billion)
3.2.8 Global Juluca HIV Treatment Market by Value
Table 20: Global Juluca HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 21: Global Juluca HIV Treatment Market by Value, 2023-2030 (US$ Million)
3.2.9 Global Descovy HIV Treatment Market by Value
Table 22: Global Descovy HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 23: Global Descovy HIV Treatment Market by Value, 2023-2030 (US$ Million)
3.2.10 Global Cabenuva HIV Treatment Market by Value
Table 24: Global Cabenuva HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 25: Global Cabenuva HIV Treatment Market by Value, 2023-2030 (US$ Billion)
3.2.11 Global Truvada HIV Treatment Market by Value
Table 26: Global Truvada HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 27: Global Truvada HIV Treatment Market by Value, 2023-2030 (US$ Million)
3.2.12 Global Atripla HIV Treatment Market by Value
Table 28: Global Atripla HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 29: Global Atripla HIV Treatment Market by Value, 2023-2030 (US$ Million)
3.2.13 Global Sunlenca (Lenacapavir) HIV Treatment Market by Value
Table 30: Global Sunlenca (Lenacapavir) HIV Treatment Market by Value, 2023-2030 (US$ Million)
3.2.14 Global VH184 HIV Treatment Market by Value
Table 31: Global VH184 HIV Treatment Market by Value; 2030 (US$ Million)
3.2.15 Global Capsid HIV Treatment Market by Value
Table 32: Global Capsid HIV Treatment Market by Value; 2027-2030 (US$ Million)
3.2.16 Global bNAbs HIV Treatment Market by Value
Table 33: Global bNAbs HIV Treatment Market by Value, 2027-2030 (US$ Million)
3.2.17 Global Islatravir HIV Treatment Market by Value
Table 34: Global Islatravir HIV Treatment Market by Value; 2024-2030 (US$ Billion)
3.2.18 Global Generics HIV Treatment Market by Value
Table 35: Global Generics HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 36: Global Generics HIV Treatment Market by Value, 2023-2030 (US$ Million)
4. Regional Market Analysis
4.1 The US HIV Treatment Market: An Analysis
4.1.1 The US HIV Treatment Market: An Overview
4.1.2 The US HIV Treatment Market by Value
Table 37: The US HIV Treatment Market by Value; 2020-2022 (US$ Billion)
Table 38: The US HIV Treatment Market by Value; 2023-2030 (US$ Billion)
4.1.3 The US HIV Treatment Market by Product (Biktarvy, Genvoya, Triumeq, Odefsey, Tivicay, Dovato, Juluca, Descovy, Cabenuva, Truvada, Atripla, and Generics)
Table 39: The US HIV Treatment Market by Product; 2022 (Percentage, %)
4.2 The US HIV Treatment Market: Product Analysis
4.2.1 The US HIV Treatment Market by Product: An Overview
4.2.2 The US Biktarvy HIV Treatment Market by Value
Table 40: The US Biktarvy HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 41: The US Biktarvy HIV Treatment Market by Value, 2023-2030 (US$ Billion)
4.2.3 The US Genvoya HIV Treatment Market by Value
Table 42: The US Genvoya HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 43: The US Genvoya HIV Treatment Market by Value, 2023-2030 (US$ Billion)
4.2.4 The US Triumeq HIV Treatment Market by Value
Table 44: The US Triumeq HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 45: The US Triumeq HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.2.5 The US Dovato HIV Treatment Market by Value
Table 46: The US Dovato HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 47: The US Dovato HIV Treatment Market by Value, 2023-2030 (US$ Billion)
4.2.6 The US Tivicay HIV Treatment Market by Value
Table 48: The US Tivicay HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 49: The US Tivicay HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.2.7 The US Odefsey HIV Treatment Market by Value
Table 50: The US Odefsey HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 51: The US Odefsey HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.2.8 The US Juluca HIV Treatment Market by Value
Table 52: The US Juluca HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 53: The US Juluca HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.2.9 The US Descovy HIV Treatment Market by Value
Table 54: The US Descovy HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 55: The US Descovy HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.2.10 The US Cabenuva HIV Treatment Market by Value
Table 56: The US Cabenuva HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 57: The US Cabenuva HIV Treatment Market by Value, 2023-2030 (US$ Billion)
4.2.11 The US Truvada HIV Treatment Market by Value
Table 58: The US Truvada HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 59: The US Truvada HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.2.12 The US Atripla HIV Treatment Market by Value
Table 60: The US Atripla HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 61: The US Atripla HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.2.13 The US Sunlenca (Lenacapavir) HIV Treatment Market by Value
Table 62: The US Sunlenca (Lenacapavir) HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.2.14 The US VH184 HIV Treatment Market by Value
Table 63: The US VH184 HIV Treatment Market by Value, 2030 (US$ Million)
4.2.15 The US Capsid HIV Treatment Market by Value
Table 64: The US Capsid HIV Treatment Market by Value, 2027-2030 (US$ Million)
4.2.16 The US bNAbs HIV Treatment Market by Value
Table 65: The US bNAbs HIV Treatment Market by Value, 2027-2030 (US$ Million)
4.2.17 The US Islatravir HIV Treatment Market by Value
Table 66: The US Islatravir HIV Treatment Market by Value, 2024-2030 (US$ Million)
4.2.18 The US Generics HIV Treatment Market by Value
Table 67: The US Generics HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 68: The US Generics HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.3 European Union + Rest of World HIV Treatment Market: An Analysis
4.3.1 European Union + Rest of World HIV Treatment Market: An Overview
4.3.2 European Union + Rest of World HIV Treatment Market by Value
Table 69: European Union + Rest of World HIV Treatment Market by Value; 2020-2022 (US$ Billion)
Table 70: European Union + Rest of World HIV Treatment Market by Value; 2023-2030 (US$ Billion)
4.3.3 European Union + Rest of World HIV Treatment Market by Product (Biktarvy, Dovato, Triumeq, Tivicay, Genvoya, Odefsey, Juluca, Descovy, Cabenuva, Truvada, and Atripla)
Table 71: European Union + Rest of World HIV Treatment Market by Product; 2022 (Percentage, %)
4.4 European Union + Rest of World HIV Treatment Market: Product Analysis
4.4.1 European Union + Rest of World HIV Treatment Market by Product: An Overview
4.4.2 European Union + Rest of World Biktarvy HIV Treatment Market by Value
Table 72: European Union + Rest of World Biktarvy HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 73: European Union + Rest of World Biktarvy HIV Treatment Market by Value, 2023-2030 (US$ Billion)
4.4.3 European Union + Rest of World Genvoya HIV Treatment Market by Value
Table 74: European Union + Rest of World Genvoya HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 75: European Union + Rest of World Genvoya HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.4.4 European Union + Rest of World Triumeq HIV Treatment Market by Value
Table 76: European Union + Rest of World Triumeq HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Table 77: European Union + Rest of World Triumeq HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.4.5 European Union + Rest of World Dovato HIV Treatment Market by Value
Table 78: European Union + Rest of World Dovato HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 79: European Union + Rest of World Dovato HIV Treatment Market by Value, 2023-2030 (US$ Billion)
4.4.6 European Union + Rest of World Tivicay HIV Treatment Market by Value
Table 80: European Union + Rest of World Tivicay HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 81: European Union + Rest of World Tivicay HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.4.7 European Union + Rest of World Odefsey HIV Treatment Market by Value
Table 82: European Union + Rest of World Odefsey HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 83: European Union + Rest of World Odefsey HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.4.8 European Union + Rest of World Juluca HIV Treatment Market by Value
Table 84: European Union + Rest of World Juluca HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 85: European Union + Rest of World Juluca HIV Treatment Market by Value, 2020-2022 (US$ Million)
4.4.9 European Union + Rest of World Descovy HIV Treatment Market by Value
Table 86: European Union + Rest of World Descovy HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 87: European Union + Rest of World Descovy HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.4.10 European Union + Rest of World Cabenuva HIV Treatment Market by Value
Table 88: European Union + Rest of World Cabenuva HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 89: European Union + Rest of World Cabenuva HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.4.11 European Union + Rest of World Truvada HIV Treatment Market by Value
Table 90: European Union + Rest of World Truvada HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 91: European Union + Rest of World Truvada HIV Treatment Market by Value, 2023-2025 (US$ Million)
4.4.12 European Union + Rest of World Atripla HIV Treatment Market by Value
Table 92: European Union + Rest of World Atripla HIV Treatment Market by Value, 2020-2022 (US$ Million)
Table 93: European Union + Rest of World Atripla HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.4.13 European Union + Rest of World Sunlenca (Lenacapavir) HIV Treatment Market by Value
Table 94: European Union + Rest of World Sunlenca (Lenacapavir) HIV Treatment Market by Value, 2023-2030 (US$ Million)
4.4.14 European Union + Rest of World VH184 HIV Treatment Market by Value
Table 95: European Union + Rest of World VH184 HIV Treatment Market by Value, 2030 (US$ Million)
4.4.15 European Union + Rest of World Capsid HIV Treatment Market by Value
Table 96: European Union + Rest of World Capsid HIV Treatment Market by Value, 2027-2030 (US$ Million)
4.4.16 European Union + Rest of World bNAbs HIV Treatment Market by Value
Table 97: European Union + Rest of World bNAbs HIV Treatment Market by Value, 2027-2030 (US$ Million)
4.4.17 European Union + Rest of World Islatravir HIV Treatment Market by Value
Table 98: European Union + Rest of World Islatravir HIV Treatment Market by Value, 2024-2030 (US$ Million)
5. Impact of COVID-19
5.1 Impact of COVID-19 on Global HIV Treatment Market
5.2 Post-COVID-19 Impact on Global HIV Treatment Market
6. Market Dynamics
6.1 Growth Driver
6.1.1 Rising HIV Prevalence
Table 99: Global Number of HIV Patients (Living with & Newly Infected); 2021 (Million)
Table 100: The US, and EU Number of HIV Patients (Prevalent, Diagnosed & Treated); 2021 (Million)
6.1.2 Advancements in Antiretroviral Therapy (ART)
Table 101: Global Coverage of Antiretroviral Treatment (ART); 2021 (Percentage, %)
Table 102: Global Coverage of Antiretroviral Treatment (ART) Among Children & Prevention Of Mother-to-child Transmission (PMTCT); 2015- 2021 (Percentage, %)
6.1.3 Rising Disposable Income
Table 103: Advanced Economies and Emerging Market & Developing Economies GDP Per Capita; 2018-2027 (US$ Thousand)
6.1.4 Increased Government Funding and Initiatives
Table 104: HIV Funding from Donor Governments; 2015-2021 (US$ Billion)
Table 105: The US Federal Domestic Discretionary Funding for HIV/AIDS; 2021-2024 (US$ Million)
6.1.5 Expansion of Generic Drugs
Table 106: FDA-Approved Generic Drugs for HIV Treatment; Until 2022
6.1.6 Growing Awareness and Testing
6.1.7 Public-private Partnerships
6.2 Challenges
6.2.1 Drug Resistance
6.2.2 Stigma, Discrimination, and Access to Treatment
6.2.3 Loss of Patent Protection
6.3 Market Trends
6.3.1 Increasing Penetration of Artificial Intelligence
Table 107: Global Artificial Intelligence (AI) Market Revenues; 2020-2023 (US$ Billion)
6.3.2 Increasing Adoption of Telemedicine
6.3.3 Development of Long-acting Injectable
6.3.4 Advances in Gene Therapy
6.3.5 Focus on Combination Therapies
7. Competitive Landscape
7.1 Global HIV Treatment Market: Competitive Landscape
7.2 Global HIV Treatment Market Players: Approved Product List
Table 108: Global HIV Treatment Market Players: Approved Product List; 2022
8. Company Profiles
8.1 Gilead Sciences, Inc.
8.1.1 Business Overview
8.1.2 Sales by Product
Table 109: Gilead Sciences, Inc. Sales by Product; 2022 (Percentage, %)
8.1.3 Business Strategy
8.2 GlaxoSmithKline Plc (ViiV Healthcare)
8.2.1 Business Overview
8.2.2 Sales by Products
Table 110: GlaxoSmithKline Plc Sales by Products; 2022 (Percentage, %)
8.2.3 Business Strategy
8.3 Merck & Co., Inc.
8.3.1 Business Overview
8.3.2 Operating Segments
Table 111: Merck & Co., Inc. Sales by Segments; 2022 (Percentage, %)
8.3.3 Business Strategy
8.4 Abbott Laboratories
8.4.1 Business Overview
8.4.2 Revenue by Category
Table 112: Abbott Laboratories Revenue by Category; 2022 (Percentage, %)
8.4.3 Business Strategy
8.5 AbbVie Inc.
8.5.1 Business Overview
8.5.2 Operating Regions
Table 113: AbbVie Inc. Net revenue by Regions; 2022 (Percentage, %)
8.5.3 Business Strategy
8.6 TEVA Pharmaceutical Industries Limited
8.6.1 Business Overview
8.6.2 Operating Segments
Table 114: TEVA Pharmaceutical Industries Ltd., Revenues by Segment; 2021 (Percentage, %)
8.6.3 Business Strategy
8.7 Johnson & Johnson (Janssen Pharmaceuticals)
8.7.1 Business Overview
8.7.2 Business Segments
Table 115: Johnson & Johnson Sales by Business Segment; 2022 (Percentage, %)
8.7.3 Business Strategy
8.8 Boehringer Ingelheim
8.8.1 Business Overview
8.8.2 Operating Business
Table 116: Boehringer Ingelheim Net Sales by Business; 2022 (Percentage, %)
8.8.3 Business Strategy
8.9 Cipla Limited
8.9.1 Business Overview
8.9.2 Operating Segments
Table 117: Cipla Limited Revenue by Segment; 2022 (Percentage, %)
8.9.3 Business Strategy
8.10 Viatris Inc.
8.10.1 Business Overview
8.10.2 Operating Segments
Table 118: Viatris Inc. Net Sales by Segment; 2022 (Percentage, %)
8.10.3 Business Strategy
8.11 Bristol-Myers Squibb Company
8.11.1 Business Overview
8.11.2 Revenue by Product
Table 119: Bristol-Myers Squibb Company Revenue by Product; 2022 (Percentage, %)
8.11.3 Business Strategy
8.12 Hetero Drugs Limited
8.12.1 Business Overview
8.12.2 Business Strategy

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings